JAGX
Jaguar Health, Inc.
There isn't enough reported data to score JAGX yet.
JAGX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
JAGX's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
JAGX PE Valuation
JAGX has no meaningful PE right now: it lost money over the past year.
JAGX Forward outlook
There aren't enough analyst estimates for JAGX to show an outlook.
JAGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$12,059.25 | +$167,905.50 |
| Q3 2025 | -$83,359.50 | +$378,891.45 |
| Q2 2025 | -$93,843.75 | +$653,875.95 |
| Q1 2025 | -$141,482.25 | +$883,962.45 |
| Q4 2024 | -$179,964.75 | +$2,680,354.95 |
JAGX lost $12,059.25 per share over the past year, a smaller loss than the year before.
JAGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.2M | -59% |
| Q1 2026 | $20.3M | +816% |
| Q4 2025 | $3.2M | -7.8% |
| Q3 2025 | $3.1M | -0.8% |
| Q4 2020 | $2.6M | +71% |
| Q3 2020 | $2.8M | +185% |
JAGX's revenue is growing: $1M last quarter, down 59% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -620% | -351 points |
| Q1 2026 | 50% | +476 points |
| Q4 2025 | -657% | -424 points |
| Q3 2025 | -235% | -1.1 points |
| Q2 2025 | -269% | N/A |
| Q1 2025 | -426% | N/A |
| Q4 2024 | -232% | N/A |
| Q3 2024 | -234% | N/A |
JAGX's operating margin was −620% last quarter, down 351 points from the same quarter a year ago.
JAGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | $8.8M | +$16.1M |
| Q1 2025 | -$7.3M | -$269K |
| Q4 2024 | -$7.8M | -$375K |
| Q3 2024 | -$6.3M | +$449K |
| Q1 2024 | -$7M | +$2.9M |
| Q4 2023 | -$7.5M | -$1M |
| Q3 2023 | -$6.8M | +$1.7M |
| Q1 2023 | -$9.9M | -$2.3M |
JAGX has burned cash in almost every quarter: −$12M over the past year, against −$28M the year before.
JAGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1772% | +51.1K shares |
| 1 year | +7455% | +53.2K shares |
| 3 years | +5394000% | +53.9K shares |
JAGX has 53,941 diluted shares, up 7455% from a year ago.
JAGX Net Leverage
JAGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
JAGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 0.1 | Oversold |
JAGX's weekly RSI is 28 (oversold) and its Stochastic is 0 (oversold).
JAGX PE vs Healthcare Sector
JAGX has no meaningful PE right now: it lost money over the past year.
JAGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.02 | 87% below |
| 20 week MA | $11.0 | 96% below |
| 50 week MA | $179.7 | 100% below |
| 100 week MA | $2,208.0 | 100% below |
JAGX is in a downtrend: it's below all four of its weekly moving averages, and 100% below its 100-week average.
JAGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $16,800.0 | $13,518.8 | -20% |
| 2025 | $13,518.8 | $572.3 | -96% |
| 2026 YTD | $572.3 | $0.40 | -100% |
JAGX has finished every year since 2024 lower, and it's down 100% so far in 2026.